Nautilus Biotech Announces IND Filing for Belerofon®, Its Oral, Long-lasting, Interferon-alpha Drug

Paris, France, 27 February 2007, Nautilus Biotech has announced that it has submitted an Investigational New Drug (IND) filing to the US Food and Drug Administration (FDA) for oral Belerofon®, its long-lasting human Interferon (IFN) alpha. Belerofon has therapeutic potential for the treatment of a number of conditions, including chronic Hepatitis C. The new drug will be administered orally - all currently marked interferon alpha drugs are administered by injection - resulting in improved safety and patient compliance.

Back to news